Loading clinical trials...
Loading clinical trials...
Clinical Study to Evaluate the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
Conditions
Interventions
Dapagliflozin 10mg Tab
Locations
1
Egypt
Medical Research Institute
Alexandria, Bab Sharqi, Egypt
Start Date
October 31, 2024
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2026
Last Updated
April 17, 2026
NCT05468034
NCT04541381
NCT03137095
NCT04852887
NCT07547774
NCT06393374
Lead Sponsor
Tanta University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions